CASI Pharmaceuticals, Inc.
CASI
$1.33
-$0.035-2.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.39% | -15.77% | -47.82% | -47.07% | -31.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.39% | -15.77% | -47.82% | -47.07% | -31.73% |
| Cost of Revenue | 52.75% | 25.78% | -34.06% | -37.18% | -21.98% |
| Gross Profit | -23.27% | -44.41% | -55.61% | -52.72% | -37.32% |
| SG&A Expenses | 10.16% | -0.94% | -2.41% | -9.32% | 4.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 99.89% | 99.97% | -287.44% | -287.44% | -- |
| Total Operating Expenses | 27.46% | 14.52% | -20.92% | -26.26% | -18.44% |
| Operating Income | -47.74% | -55.11% | -23.45% | -7.72% | -2.85% |
| Income Before Tax | -34.76% | -49.04% | 18.59% | 30.01% | 15.88% |
| Income Tax Expenses | -- | -- | -100.05% | -100.05% | -104.09% |
| Earnings from Continuing Operations | -35.13% | -49.50% | 22.49% | 33.32% | 20.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 77.11% | 53.95% | 32.21% |
| Net Income | -32.91% | -45.73% | 23.45% | 33.68% | 20.74% |
| EBIT | -47.74% | -55.11% | -23.45% | -7.72% | -2.85% |
| EBITDA | -54.02% | -59.01% | -21.70% | -6.36% | -1.12% |
| EPS Basic | -10.01% | -25.16% | 25.72% | 33.26% | 19.59% |
| Normalized Basic EPS | -25.30% | -43.45% | -24.14% | -4.89% | -19.26% |
| EPS Diluted | -9.94% | -25.06% | 25.68% | 33.22% | 19.55% |
| Normalized Diluted EPS | -25.30% | -43.45% | -24.14% | -4.89% | -19.26% |
| Average Basic Shares Outstanding | 18.65% | 14.80% | 3.59% | -0.40% | -1.21% |
| Average Diluted Shares Outstanding | 18.65% | 14.80% | 3.59% | -0.40% | -1.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |